PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40631030,"Physician specialty shapes hypothetical self-treatment choices for locally advanced non-small cell lung cancer: Is the ""best"" option subjective?",2025,Mara B Antonoff; Corinne Faivre-Finn; Sanjay Popat; Brendon M Stiles,"Thoracic and Cardiovascular Surgery, UT MD Anderson Cancer Center, Houston, Tex.; Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Thoracic Oncology, The Royal Marsden, London, United Kingdom.; Thoracic Surgery, Montefiore Medical Center, Bronx, NY.",
40630397,T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.,2025,Joel Wight; Eliza A Hawkes,Austin Health Heidelberg Australia.; Austin Health Heidelberg Australia.,
40629908,Sex parity in stimulation of murine lymphocyte trafficking in response to fever-range systemic thermal therapy.,2025,Michelle M Appenheimer; Arwen A Tisdale; Daniel T Fisher; Han Yu; Elizabeth A Repasky; Sharon S Evans,"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",
40629516,Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium.,2025,Andrew J Portuguese; Ariel F Grajales-Cruz; Andre De Menezes Silva Corraes; Krina K Patel; Megan M Herr; Saurabh Chhabra; Ricardo D Parrondo; Yi Lin; Faiz Anwer; Mariola Vazquez-Martinez; Omar Castaneda Puglianini; Doris K Hansen,"Fred Hutchinson Cancer Center, Seattle, WA, United States.; Moffitt Cancer Center, Tampa, United States.; Mayo Clinic, Rochester, Minnesota, United States.; UT-MD Anderson Cancer Center, Houston, TX, United States.; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.; Mayo Clinic Comprehensive Cancer Center, Arizona, United States.; Mayo Clinic Comprehensive Cancer Center, United States.; Mayo Clinic, Rochester, MN, United States.; Cleveland Clinic, Cleveland, OH, United States.; Moffitt Cancer Center, United States.; Moffitt Cancer Center, Tampa, FL, United States.; Moffitt Cancer Center, Tampa, United States.",
40629415,CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas.,2025,Anna Maria Chiaravalli; Michele Cerati; Stefano La Rosa,"Unit of Pathology, ASST Sette-Laghi, 21100, Varese, Italy.; Unit of Pathology, ASST Sette-Laghi, 21100, Varese, Italy.; Unit of Pathology, ASST Sette-Laghi, 21100, Varese, Italy.",
40628732,Glioblastoma at the crossroads: current understanding and future therapeutic horizons.,2025,Sujata Prasad,"MLM Medical Labs LLC, Oakdale, MN, USA.",
40628625,"Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.",2025,Thomas X Lemarchand; Luise Britz; Rosanne Dunn,"TPL Path Labs GmbH, StageBio Company, Freiburg im Breisgau 79111, Germany.; TPL Path Labs GmbH, StageBio Company, Freiburg im Breisgau 79111, Germany.; Haemalogix Ltd, Sydney, New South Wales 2001, Australia.",
40628289,Understanding antibody-target antigen interactions and the avidity effect using mathematical modelling.,2025,Armin Sepp; James Yates,"Certara UK Limited, Sheffield, UK.; GSK plc, Stevenage, UK.",
40628269,The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1,2025,Tesia Bobrowski; Brad R Rosenberg,"Department of Microbiology, ISMMS, New York, NY 10029, USA.; Department of Microbiology, ISMMS, New York, NY 10029, USA.",
40628264,Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma.,2025,Sijing Li; Omar Motiño; Flavia Lambertucci; Jonathan Pol; Hui Chen; Long Pan; Sylvère Durand; Lucie Poupel; Christophe Klein; Léa Montégut; María Pérez-Lanzón; Gerasimos Anagnostopoulos; Uxia Nogueira-Recalde; Alexandra Cerone; Fanny Aprahamian; Yanbing Dong; Manuela Lizarralde-Guerrero; Enfu Xue; Peng Liu; Liwei Zhao; Hui Pan; Vincent Carbonnier; Sylvie Lachkar; Ester Gloria Saavedra Díaz; Chantal Desdouets; Sabine Colnot; Oliver Kepp; Isabelle Martins; Laurence Zitvogel; Jessica Zucman-Rossi; Guido Kroemer,"Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; CHICS, Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; CHICS, Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Fundación Profesor Novoa Santos, A Coruña, Spain.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Departamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología, Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.; Team Genomic Instability, Metabolism, Immunity and Liver Tumorigenesis Laboratory, Equipe Labellisée LIGUE 2023, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris, Paris, France.; Team ""Oncogenic functions of β-catenin Signaling in the Liver (ONCOLIV)"", Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Gustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée Par La Ligue Contre le Cancer, 94800 Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Gustave Roussy, 94805 Villejuif, France.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Electronic address: kroemer@orange.fr.",kroemer@orange.fr.
40627846,EML4-ALK rearrangement creates a distinctive myeloid cell-dominant immunosuppressive microenvironment in lung cancer.,2025,Yukari Nishito; Hideaki Mizuno; Yukiko Sonobe; Yoko Kayukawa; Toru Maruyama; Yukihiro Mizoguchi; Shigehisa Kitano; Risa Mitsumori; Kouichi Ozaki; Shumpei Niida; Kazuki Yasuda; Hiroyuki Tsunoda,"Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan.; Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.; Roche (Switzerland), Basel, Basel-stadt, Switzerland.; Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan.; Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan.; National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.; National Center for Geriatrics and Gerontology, Obu, Japan.; National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.; National Center for Global Health and Medicine, Japan.; Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.",
40627813,RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).,2025,Michael K Wong; Judith Michels; Jiaxin Niu; Tawnya Lynn Bowles; Caroline Gaudy-Marqueste; Praveen K Bommareddy; Junhong Zhu; Marcus Viana; Jeannie W Hou; Robert S Coffin,"Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.; Banner MD Anderson Cancer Center, Gilbert, AZ, USA.; Intermountain Medical Center, Murray, UT, USA.; Aix-Marseille Université, APHM, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, UM105, Hôpital Timone, CEPCM, Dermatology and Skin Cancer Department, Marseille, France.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.",
40627669,HPV vaccine uptake among adolescent girls in Nigeria: The complex role of caregivers' education.,2025,Ifeanyi Nsofor,"Family Health Initiative, Abuja, Nigeria.",
40627448,NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.,2025,Barzin Y Nabet; Velimir Gayevskiy; Alberto Chiappori; David S Shames,"Genentech Inc., South San Francisco, United States of America.; Genentech Inc., South San Francisco, United States of America.; Thoracic Oncology Program, Moffitt Cancer Center, Tampa, United States of America.; Genentech Inc., South San Francisco, United States of America.",
40627445,"SARC028 samples reveal an interplay between TGFβ, interferon signaling and low HLA class I expression as contributors to Ewing sarcoma checkpoint blockade resistance.",2025,Melissa Burgess,"U Pittsburgh, Pittsburgh, PA, United States.",
40627401,Controlling T cell-tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy.,2025,Yuxuan Zhang; Jinjin Wang; Guangchao Qing; Yongchao Wang; Xianlei Li; Ting Luo; Yi-Feng Wang; Lu Liu; Yufei Wang; Qiankun Ni; Shuyi Li; Junge Chen; Fangzhou Li; Xing-Jie Liang,"Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.",
40626955,Design and Characterization of Prodrugged Anti-CTLA-4 Antibodies.,2025,Sayumi Yamazoe; Mary Huber; Srikanth Kotapati; Rahima Akter; Aarti Jashnani; Suprit Deol; Christine Bee; John Engelhart; Yam B Poudel; Stanley Krystek; Mohan Srinivasan; Arvind Rajpal; Yong Zhang; Pavel Strop; Chetana Rao; John Haugner,"Bristol-Myers Squibb Co, Discovery Biologics, 700 Bay road, 94063, Redwood city, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol-Myers Squibb Company, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and Development, UNITED STATES OF AMERICA.; Bristol Myers Squibb Co, Research and development, UNITED STATES OF AMERICA.",
40626883,Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti-PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer.,2025,Stéphane Fattori; Laurent Gorvel; Marie-Sarah Rouvière; Samuel Granjeaud; Amira Ben Amara; Manon Richaud; Nicolas Boucherit; Grégoire Bellan; Jean-Jacques Fournié; Anne-Sophie Chrétien,"Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, Marseille, France.; Télécom Paris, France.; INSERM, Toulouse, France.; Inserm, Marseille, France.",
40626667,Lights and shadows of microsatellite status characterization in gastrointestinal cancers in the era of cancer precision therapy.,2025,Paola Parente; Luisa Toffolatti,"Unit of Pathology, Fondazione IRCCS Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Foggia, Italy.; Surgical Pathology Unit, ULSS2 Marca Trevigiana, Treviso, Italy.",
40626281,Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.,2025,Mathias Heikenwälder,"Division of Chronic Inflammation and Cancer, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany.",
40626041,Perspective on recent developments and challenges in regulatory and systems genomics.,2025,Alejandra Medina-Rivera,"Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro 76230, Mexico.",
40626017,Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.,2025,Rebecca Alexandra Dent; Veronique Kiak-Mien Tan; Frances Victoria F Que; Sun-Young Kong,"Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Breast Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Internal Medicine and Oncology, St Luke's Medical Center, Quezon City and Global City, Metro Manila, Philippines.; Department of Laboratory Medicine and Genetic Counselling Clinic, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.",
40625771,A rare case of primary prostate melanoma with extensive secondaries: case report.,2025,Kumanan Jayaraman; Rejeesh Selvaganesan; Binitta Sherin,"Oncology, KIMS Health, TVM Main Road, Chukankadai, Nagercoil, 629003 India.; Surgical Gastroenterology, KIMS Health, TVM Main Road, Chukankadai, Nagercoil, 629003 India.; Pathology, KIMS Health, TVM Main Road, Chukankadai, Nagercoil, 629003 India.",
40624367,"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.",2025,Sonja Zweegman; Niels W C J van de Donk; Elena Zamagni; Paula Rodriguez-Otero; Christoph Driessen; Michele Cavo; Mohamad Mohty; Jesus San-Miguel,"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ""Seràgnoli"", Bologna, Italy.; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.; Department of Medical Oncology and Hematology, HOCH Health Ostchweiz, St. Gallen, Switzerland.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.; Centre de Recherche Saint-Antoine INSERM UMRs938, Sorbonne Université, Paris, France.; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.",
40624238,IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR,2025,Kenneth H Gouin; Hsiang-Han Chen; Aagam Shah; Carlos Eduardo de Andrea; Belén Navarro-Rubio; Irantzu Serrano-Mendioroz; Esther Navarro Manzano; Alexandra M Satty; Brady Rippon; Xi Kathy Zhou; Joseph M Scandura; Elena García-Martínez; Francisco Ayala de la Peña; María Esperanza Rodríguez-Ruiz; Víctor Sánchez-Margalet; Luis de la Cruz-Merino; Stephen L Shiao; Heather L McArthur; Simon R V Knott,"Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Department of Anatomy, Physiology and Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Centro Regional de Hemodonación, Murcia, Spain.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.; Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, Universidad de Sevilla, Sevilla, Spain.; Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, Universidad de Sevilla, Sevilla, Spain.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.",
40623886,"Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial - protocol for a phase II study.",2025,Sagun Parakh; Harriet Gee; Courtney Wheeler; Bridget Rooney; Rebecca Montgomery; Susan Harden; Laurel Schmidt,"Olivia Newton-John Cancer Centre at Austin Health, Heidelberg, Victoria, Australia.; Radiation Oncology Network, Western Sydney Local Health District, Sydney, New South Wales, Australia.; Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia.; Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia.; Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia.; Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; St George Cancer Care Centre, Kogarah, Sydney, Australia.",
40623769,Role of microbiome in cancer progression.,2025,Akshay Basi,"NC Flow Cytometry and Cellular Imaging Core Facility, MD Anderson Cancer Center, Houston, TX, United States.",
40623767,The role of microbiome in CAR-T cell therapy.,2025,Travis D Kerr; Daniel J McGrail,"Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, United States.; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, United States.",
